Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

4.485 -0.105 (-2.29%)
Streaming Delayed Price Updated: 3:04 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Top 4 Health Care Stocks You May Want To Dump In February ↗
As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
A Preview Of Ironwood Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Chart Of The Day: Ironwood Pharma - Gastrointestinal Products ↗
Via Talk Markets
News headline image
Earnings Preview For Ironwood Pharmaceuticals ↗
 
Via Benzinga
News headline image
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... 
Via Newsfile
News headline image
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 ↗
 
Via Benzinga
News headline image
Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday. 
Via Benzinga
News headline image
Orchestra BioMed, Vital Farms And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround ↗
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned. 
Via The Motley Fool
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.